Stay updated with breaking news from Appili Share. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million on April 2, 2024. Under the terms of the Arrangement Agreement, shareholders of Appili will...
Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million on April 2, 2024. Under the terms of the Arrangement Agreement, shareholders of Appili will...
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED